Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Ark Invest bought shares of CoreWeave, Scribe Therapeutics and Freenome on Monday, with the three stocks trading 28% to 57% below previous highs; CoreWeave subsequently hit another 52-week low, while Freenome rose 7% on Monday. CoreWeave's latest-quarter revenue grew 113% but it remains loss-making, Scribe says its cash can fund operations through the first half of 2029, and Freenome recently received FDA clearance for a lung cancer screening test.

Analysis

Ark’s buying is a weak signal: position size and cost basis are unknown, and buying a falling stock does not establish that its funding risk is priced in. For CoreWeave, the key second-order risk is not simply AI demand but who finances the build-out and whether contracted demand translates into cash generation before debt and infrastructure commitments bite. Higher funding costs can pressure both CoreWeave and customers’ ability to sustain compute spending; lower utilization or faster hardware obsolescence would amplify that exposure. Conversely, durable customer commitments and improving cash conversion could make the recent multiple reset excessive.

Over the next 1–3 months, focus on financing terms, customer concentration, utilization, capex, and any guidance change—not Ark’s trades. Over 6–18 months, the test is whether growth converts into cash flow without repeated external funding. The article’s loss and forecast claims warrant checking against filings; analyst estimates are not a funding plan. For Scribe Therapeutics, reported runway reduces near-term financing pressure only if burn stays on plan; clinical validation remains the value driver. For Freenome, regulatory clearance is not proof of reimbursement, physician adoption, or commercial scale. The contrarian risk is treating steep declines as bargains before these milestones are independently demonstrated.

Key Decisions for Investors

• Do not use Ark’s purchase as a standalone buy signal in CRWV. Keep exposure limited until filings clarify debt maturities, borrowing costs, customer commitments, utilization, and capex funding.
• For a bearish CRWV expression, consider a defined-risk put spread only after a failed stabilization or a deterioration in funding/cash-flow disclosures; avoid an unhedged short given the potential for sharp AI-demand-driven rebounds. Reassess if utilization and cash conversion improve while funding needs moderate.
• Track Scribe Therapeutics’ quarterly cash burn against its company-reported runway and upcoming clinical milestones; treat any burn acceleration or financing announcement as a thesis warning, not as a reason to infer imminent failure.
• For Freenome, wait for evidence of test uptake, reimbursement, and repeatable commercial demand after regulatory milestones before assigning a durable revenue thesis. Clearance without adoption would falsify the bullish commercialization case.